Genmab — August 2016
-
-
Fra Q&A: We currently work with models for the US plus the five largest countries in the EU estimating the fourth line market to be roughly 20,000 patients, the second and third line market is estimated to be around 45,000 patients (these are the populations targetted in POLLUX and CASTOR)..
-
Jeg kan bare godt lide at tage fremgangen lidt mere roligt - hvis eksempelvis en patient ikke længere responderer på førstelinie behandling (eks. Dara-Rev-Dex) - hvad giver man så herefter? En kombi hvor Dara stadig indgår og ikke Rev eller måske omvendt eller en kombi hvor ingen af dem er med.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind